2023 ´ëÇÑÇ÷¾×ÇÐȸ ¸¸¼º°ñ¼ö¼º¹éÇ÷¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö : 2023-09-23
±³À°ÀÏÀÚ : 2023-09-23
±³À°Àå¼Ò : ¼¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ ´ë°´ç
±³À°ÁÖÁ¦ : 2023 ´ëÇÑÇ÷¾×ÇÐȸ ¸¸¼º°ñ¼ö¼º¹éÇ÷¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¸¸¼º°ñ¼ö¼º¹éÇ÷º´¿¬±¸È¸
´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ : hematology@kamslor.kr
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀÎ : 60¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 3 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í Àü¹®ÀÇ 50,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°´ç 09:30~10:05 Third-line treatment for CML(chronic myeloid leukemia) ÇÑÀçÁØ(°æÈñÀÇ´ë)
±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°´ç 10:05~10:40 Treatment in advanced phase (AP/BC) of CML(chronic myeloid leukemia) ±è°æÇÏ(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°´ç 11:00~11:15 ASTER-P ¹Ú¼º¿ì(°æ»óÀÇ´ë )
±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°´ç 11:15~11:30 ASTER-A ¾öÁöÀº(ÇѾçÀÇ´ë )
±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°´ç 11:30~11:45 NGS( next generation sequencing) for ABL1 mutation ½Å»õ¾Ï(¿¬¼¼ÀÇ´ë )
±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°´ç 11:45~12:00 HBV(hepatitis B virus) prophylaxis in TKI-treated CML(chronic myeloid leukemia) ÀÌÀ¯Áø(¿ï»êÀÇ´ë )
±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°´ç 13:00~13:15 Ponatinib dose optimization ÀÌÁ¤¿Á(¼¿ïÀÇ´ë)
±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°´ç 13:15~13:30 Dasatinib dose optimization ±è»ó¾Æ(¼¿ïÀÇ´ë )
±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°´ç 13:30~13:45 Imatinib as 1st line therapy in very elderly CML(chronic myeloid leukemia)) patients Á¶ÁøÇö(ÀÎÇÏÀÇ´ë )
±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°´ç 13:45~14:00 Immune effect on TFR(total fertility rate ) ÃÖÀ±¼®(¾ÆÁÖÀÇ´ë )
±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°´ç 14:00~14:15 Nilotinib dose optimization ¹ÚÇö°æ(¼¿ïÀÇ´ë )
±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°´ç 14:15~14:30 Asciminib as salvage therapy in real-world CML(chronic myeloid leukemia))practice ÃÖÀºÁö(¿ï»êÀÇ´ë )